^
Association details:
| Biomarker: | FLT3 D835F |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Vanflyta (quizartinib) (FLT3 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Excerpt:
one novel activation loop mutation, D835F, was identified in a single patient. This mutation confers substantial in vitro resistance to AC220 (Supplementary Fig. 1) and cross-resistance to sorafenib (data not shown), and was probably not detected in our saturation mutagenesis screen because its creation requires a two-nucleotide substitution.
DOI:
https://dx.doi.org/10.1038%2Fnature11016
Trial ID:
